Zheng Quan Ri Bao Wang·2026-02-05 11:11Group 1: Market Overview - The global sales of GLP-1 drugs have surpassed Merck's Keytruda, with Eli Lilly's Tirzepatide generating $36.5 billion and Novo Nordisk's Semaglutide achieving $36.1 billion in 2025 [1] - The sales of Tirzepatide's weight loss indication increased by 175% year-on-year, while the diabetes indication grew by 99% [1] - The potential patient market for weight loss is significantly large, indicating a strong demand for GLP-1 drugs [1] Group 2: Company Developments - Several domestic companies, including Innovent Biologics, Jiangsu Hengrui Medicine, Tonghua Dongbao, and East China Pharmaceutical, are actively developing GLP-1 drugs to meet weight loss market demands [2] - Innovent Biologics' GLP-1 weight loss drug, Sema, has been approved for sale in China, contributing to the company's revenue growth, which is expected to exceed 10 billion yuan in 2025 [3] - Hengrui Medicine is developing HRS9531, which shows promising results in weight loss and blood sugar control, while also improving cardiovascular and renal risk factors [4] Group 3: Competitive Strategies - Companies are adopting differentiated strategies in drug development, such as creating oral formulations, extending drug half-lives, and innovating sales models [5] - Hengrui Medicine is focusing on developing a GLP-1/GIP dual receptor agonist, which aims to enhance efficacy and safety [5] - Tonghua Dongbao is also working on a GLP-1/GIP dual receptor agonist, with clinical trials progressing smoothly [5] Group 4: Research and Development Focus - Innovent Biologics is expanding its research pipeline to include long-acting, oral, and multi-target projects, aiming to provide more effective treatment options [6] - East China Pharmaceutical is developing an oral small molecule GLP-1 drug, with successful completion of all subject enrollments for its clinical phase III study in weight management [6]